Gossamer Bio, Inc. 8-K

What Happened
Gossamer Bio, Inc. (GOSS) announced on July 1, 2026 (filed via Form 8‑K) the initial conversion rate for its 7.50% Convertible Senior Secured First Lien Notes due 2030 and the initial exercise price for related Purchase Warrants. The company set the conversion rate at 5,347.5936 shares of common stock per $1,000 principal amount of the 2030 Convertible Notes (approximately $0.19 per share) and the initial warrant exercise price at $0.34 per whole share.

Key Details

• Conversion rate: 5,347.5936 shares per $1,000 principal of the 2030 Convertible Notes (≈ $0.19 per share).
• Notes: 7.50% Convertible Senior Secured First Lien Notes due 2030.
• Warrant exercise price: $0.34 per whole share for the Purchase Warrants.
• Disclosure date: Press release issued July 1, 2026 (press release furnished as Exhibit 99.1 to the 8‑K).

Why It Matters
These terms define how many shares holders of the 2030 Convertible Notes would receive if they convert and the price at which warrant holders can buy shares, both of which affect the potential number of outstanding shares and investor ownership percentages. The conversion price (~$0.19) and warrant exercise price ($0.34) are key inputs for assessing potential dilution and the economic impact of conversions or warrant exercises.